Insider Stock Buying Of Candel Therapeutics Delivers Return On US$3.00m Investment
Candel Therapeutics Provides Clinical and Financial Update, Outlines 2025 Milestones for CAN-2409 and CAN-3110 Programs
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025
How Is The Market Feeling About Candel Therapeutics?
2025 Biotech Outlook: Small-cap Innovators Tackling Chronic and Rare Diseases | NASDAQ:CADL
Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
